Ankersen Dorit Vedel, Weimers Petra, Marker Dorte, Teglgaard Peters-Lehm Charlotte, Bennedsen Mette, Rosager Hansen Malte, Olsen Jens, Elmegaard Madsen Maria, Burisch Johan, Munkholm Pia
Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.
Incentive, Holte, Denmark.
Scand J Gastroenterol. 2021 May;56(5):520-529. doi: 10.1080/00365521.2021.1892176. Epub 2021 Feb 28.
Costs of using eHealth in inflammatory bowel disease (IBD) management has only been assessed for short follow-up periods. The primary aim was to compare the direct costs of eHealth (cases) relative to standard care (matched controls) for IBD during three years of follow-up.
The study design was a retrospective, registry-based follow-up study of patients diagnosed with IBD two years prior, and three years subsequent, to their enrolment in eHealth. Cases were matched 1:4 with controls receiving standard care based on diagnosis, gender, biologics (yes/no) and age (+/- 5 years).
We identified 116 cases (76 (66%) with ulcerative colitis (UC) and 40 (34%) with Crohn's disease (CD)) and matched them with 433 controls. IBD-related outpatient costs were only significantly higher for cases in the year of their inclusion in eHealth (€2,949 vs. €1,621 per patient, =.01). Mean IBD-related admission costs tended to fall after enrolment in eHealth, with mean admission costs per patient at year 3 of follow-up of €74 for cases and €383 for controls ( = .02). Linear extrapolation of the reduction in costs beyond year 3 after enrolment in eHealth revealed that eHealth would be cost neutral or saving, relative to standard care, from year 4.
IBD-related outpatient costs in both groups were similar and only significantly higher for cases in the year of their enrolment in eHealth, with admission costs typically falling after a patient's inclusion in eHealth. Estimation revealed eHealth to be cost neutral or saving from year 4.
在炎症性肠病(IBD)管理中使用电子健康技术的成本仅在短期随访期内进行过评估。主要目的是比较在三年随访期内,IBD患者使用电子健康技术(病例组)相对于标准护理(匹配对照组)的直接成本。
本研究设计为一项基于登记的回顾性随访研究,研究对象为在纳入电子健康技术之前两年被诊断为IBD且在纳入之后三年的患者。根据诊断、性别、生物制剂使用情况(是/否)和年龄(±5岁),病例组与接受标准护理的对照组按1:4进行匹配。
我们确定了116例病例(76例(66%)为溃疡性结肠炎(UC),40例(34%)为克罗恩病(CD)),并将其与433例对照组进行匹配。仅在病例组纳入电子健康技术的当年,IBD相关的门诊费用显著更高(每位患者2949欧元对1621欧元,P = 0.01)。在纳入电子健康技术后,IBD相关的平均住院费用呈下降趋势,随访第3年时,病例组每位患者的平均住院费用为74欧元,对照组为383欧元(P = 0.02)。对纳入电子健康技术后第3年之后成本降低情况进行线性外推显示,从第4年起,相对于标准护理,电子健康技术将实现成本中性或节省成本。
两组中与IBD相关的门诊费用相似,仅在病例组纳入电子健康技术的当年显著更高,患者纳入电子健康技术后住院费用通常会下降。估计显示从第4年起电子健康技术将实现成本中性或节省成本。